Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Did you know? CSL is investigating a potential treatment to improve the health of people living with end-stage kidney disease…
An associate professor living with Hereditary Angioedema encourages fellow patients to “never give up and try to persist in y…
Primary immune deficiency is a group of rare diseases that makes people vulnerable to frequent and hard-to-treat infections.
Antti Kourula, CSL Behring’s Vice President of Commercial Development for Hematology, recently traveled to the Central Asian …
CSL joins with the global bleeding disorders community – including women and girls – to support empowerment and access to tre…
The research doesn’t stop just because a new treatment has been approved for use by patients. We talked with CSL’s Andres Bra…
On February 28, CSL will illuminate landmarks in the United States, Switzerland and Germany. “Take a few moments to reflect o…
Kids in a rare disease research trial deserve extra care. That’s why CSL decided to be the first ever to provide “Clinical Co…
Their condition is so little known, patients who live with hereditary angioedema (HAE) endure diagnostic delays characterized…
Learn what happens when someone has chronic inflammatory demyelinating polyneuropathy and about the role of immunoglobulin th…
Inside your cells, these essential elements contain specific instructions – and that’s why they’re the target of 21st century…
Did you know? Kids who have bleeding disorders play baseball. A longtime coach for CSL Behring’s Gettin’ In the Game Junior N…
Americas
Asia Pacific
Middle East
Europe
